deltatrials
Terminated PHASE1 NCT00732745

Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase I/II Study of the Combination of Oxaliplatin / Docetaxel and ZACTIMA for the Treatment of Advanced Cancers of the Esophagus and Gastroesophageal Junction

Sponsor: Case Comprehensive Cancer Center

Conditions Adenocarcinoma of the Gastroesophageal Junction Esophageal Cancer
Interventions docetaxel oxaliplatin placebo vandetanib
Updated 6 times since 2017 Last updated: Aug 19, 2011 Started: Oct 31, 2008 Primary completion: Jun 30, 2010

A PHASE1 clinical study on Adenocarcinoma of the Gastroesophageal Junction and Esophageal Cancer, this trial is terminated or withdrawn. The trial is conducted by Case Comprehensive Cancer Center and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States